INTRODUCTION: Omadacycline is a new analog of the tetracycline class active against atypical bacteria, as well as against staphylococci, including methicillin-resistant strains, and .
AREAS COVERED: This review has summarized the available clinical evidence on the use of oral Omadacycline in the treatment of community-acquired pneumonia (CAP) and described the mechanism of action, pharmacokinetic/pharmacodynamic (PK/PD) parameters in healthy and special populations and the latest research on Omadacycline.
EXPERT OPINION: The available clinical evidence on oral Omadacycline for the treatment of CAP shows that its properties provide reliable empirical coverage for pathogens such as , , and species of , , and . Omadacycline is also active against methicillin-resistant (MRSA); penicillin-resistant and multidrug-resistant , , and ; and vancomycin-resistant spp. A dose of 450 mg orally once daily is recommended, followed by a maintenance dose of 300 mg orally once daily. Importantly, Omadacycline does not require dose adjustment for patients based on BMI, age, gender, or renal or hepatic impairment.
